International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark.
J Infect. 2010 Jun;60(6):452-7. doi: 10.1016/j.jinf.2010.03.017. Epub 2010 Mar 27.
A retrospective study on isoniazid-resistant tuberculosis (TB) was conducted in the low-burden country, Denmark (DK). The aim was to describe treatment outcome and transmission and to evaluate a mutation analysis for high- and low-level isoniazid resistance detection.
In the period 2002-2007, all isoniazid-resistant TB-cases were included. Molecular genotyping was performed by standardized IS6110 restriction fragment length polymorphism (RFLP). Identical isoniazid-resistant genotypes, indicating ongoing transmission, were identified from the national RFLP database. An analysis of rifampin (rpoB) and high- or low-level (katG, inhA) isoniazid resistance mutations was performed on subcultured strains.
There were 1825 culture-confirmed cases, of which 111 (6.1%) had monoresistance or polyresistance to isoniazid. Successful short- and long-term treatment outcome was achieved in 80% and 95%, respectively. Overall, the mutation analysis predicted 94% of isoniazid resistance in 111 strains. The katG S315T1 and inhA C15T1 mutations correctly identified high- and low-level isoniazid resistance in 84% and 84% of the strains, respectively.
Isoniazid-resistant TB has a good prognosis in DK. High- and low- level isoniazid resistance does not affect treatment outcome of standard modified treatment. Rapid mutation detection identified the majority of isoniazid-resistant cases however the impact on treatment outcome remains to be determined.
在低负担国家丹麦(DK)进行了一项异烟肼耐药结核病(TB)的回顾性研究。目的是描述治疗结果和传播情况,并评估突变分析在高低水平异烟肼耐药检测中的应用。
在 2002-2007 年期间,纳入了所有异烟肼耐药 TB 病例。采用标准化的 IS6110 限制片段长度多态性(RFLP)进行分子基因分型。从国家 RFLP 数据库中识别出表明正在传播的相同异烟肼耐药基因型。对培养的菌株进行利福平(rpoB)和高低水平(katG、inhA)异烟肼耐药突变的分析。
共发现 1825 例培养确诊病例,其中 111 例(6.1%)对异烟肼单药耐药或多药耐药。短期和长期治疗成功率分别为 80%和 95%。总体而言,突变分析预测了 111 株菌株中 94%的异烟肼耐药性。katG S315T1 和 inhA C15T1 突变分别正确识别了 84%和 84%的高、低水平异烟肼耐药性。
在 DK,异烟肼耐药性结核病具有良好的预后。高低水平异烟肼耐药性不影响标准改良治疗的治疗结果。快速的突变检测鉴定了大多数异烟肼耐药病例,但对治疗结果的影响仍有待确定。